Physician response to implementation of genotype-tailored antiplatelet therapy

J. F. Peterson, J. R. Field, K. M. Unertl, J. S. Schildcrout, D. C. Johnson, Y. Shi, I. Danciu, J. H. Cleator, J. M. Pulley, J. A. Mcpherson, J. C. Denny, Michael Laposata, D. M. Roden, K. B. Johnson

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Physician responses to genomic information are vital to the success of precision medicine initiatives. We prospectively studied a pharmacogenomics implementation program for the propensity of clinicians to select antiplatelet therapy based on CYP2C19 loss-of-function variants in stented patients. Among 2,676 patients, 514 (19.2%) were found to have a CYP2C19 variant affecting clopidogrel metabolism. For the majority (93.6%) of the cohort, cardiologists received active and direct notification of CYP2C19 status. Over 12 months, 57.6% of poor metabolizers and 33.2% of intermediate metabolizers received alternatives to clopidogrel. CYP2C19 variant status was the most influential factor impacting the prescribing decision (hazard ratio [HR] in poor metabolizers 8.1, 95% confidence interval [CI] [5.4, 12.2] and HR 5.0, 95% CI [4.0, 6.3] in intermediate metabolizers), followed by patient age and type of stent implanted. We conclude that cardiologists tailored antiplatelet therapy for a minority of patients with a CYP2C19 variant and considered both genomic and nongenomic risks in their clinical decision-making.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StateAccepted/In press - 2016
Externally publishedYes

Fingerprint

clopidogrel
Genotype
Physicians
Confidence Intervals
Therapeutics
Precision Medicine
Pharmacogenetics
Stents
Cytochrome P-450 CYP2C19
Cardiologists

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Peterson, J. F., Field, J. R., Unertl, K. M., Schildcrout, J. S., Johnson, D. C., Shi, Y., ... Johnson, K. B. (Accepted/In press). Physician response to implementation of genotype-tailored antiplatelet therapy. Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.331

Physician response to implementation of genotype-tailored antiplatelet therapy. / Peterson, J. F.; Field, J. R.; Unertl, K. M.; Schildcrout, J. S.; Johnson, D. C.; Shi, Y.; Danciu, I.; Cleator, J. H.; Pulley, J. M.; Mcpherson, J. A.; Denny, J. C.; Laposata, Michael; Roden, D. M.; Johnson, K. B.

In: Clinical Pharmacology and Therapeutics, 2016.

Research output: Contribution to journalArticle

Peterson, JF, Field, JR, Unertl, KM, Schildcrout, JS, Johnson, DC, Shi, Y, Danciu, I, Cleator, JH, Pulley, JM, Mcpherson, JA, Denny, JC, Laposata, M, Roden, DM & Johnson, KB 2016, 'Physician response to implementation of genotype-tailored antiplatelet therapy', Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.331
Peterson, J. F. ; Field, J. R. ; Unertl, K. M. ; Schildcrout, J. S. ; Johnson, D. C. ; Shi, Y. ; Danciu, I. ; Cleator, J. H. ; Pulley, J. M. ; Mcpherson, J. A. ; Denny, J. C. ; Laposata, Michael ; Roden, D. M. ; Johnson, K. B. / Physician response to implementation of genotype-tailored antiplatelet therapy. In: Clinical Pharmacology and Therapeutics. 2016.
@article{799d08619ed249cc94cb46f2b847df5d,
title = "Physician response to implementation of genotype-tailored antiplatelet therapy",
abstract = "Physician responses to genomic information are vital to the success of precision medicine initiatives. We prospectively studied a pharmacogenomics implementation program for the propensity of clinicians to select antiplatelet therapy based on CYP2C19 loss-of-function variants in stented patients. Among 2,676 patients, 514 (19.2{\%}) were found to have a CYP2C19 variant affecting clopidogrel metabolism. For the majority (93.6{\%}) of the cohort, cardiologists received active and direct notification of CYP2C19 status. Over 12 months, 57.6{\%} of poor metabolizers and 33.2{\%} of intermediate metabolizers received alternatives to clopidogrel. CYP2C19 variant status was the most influential factor impacting the prescribing decision (hazard ratio [HR] in poor metabolizers 8.1, 95{\%} confidence interval [CI] [5.4, 12.2] and HR 5.0, 95{\%} CI [4.0, 6.3] in intermediate metabolizers), followed by patient age and type of stent implanted. We conclude that cardiologists tailored antiplatelet therapy for a minority of patients with a CYP2C19 variant and considered both genomic and nongenomic risks in their clinical decision-making.",
author = "Peterson, {J. F.} and Field, {J. R.} and Unertl, {K. M.} and Schildcrout, {J. S.} and Johnson, {D. C.} and Y. Shi and I. Danciu and Cleator, {J. H.} and Pulley, {J. M.} and Mcpherson, {J. A.} and Denny, {J. C.} and Michael Laposata and Roden, {D. M.} and Johnson, {K. B.}",
year = "2016",
doi = "10.1002/cpt.331",
language = "English (US)",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Physician response to implementation of genotype-tailored antiplatelet therapy

AU - Peterson, J. F.

AU - Field, J. R.

AU - Unertl, K. M.

AU - Schildcrout, J. S.

AU - Johnson, D. C.

AU - Shi, Y.

AU - Danciu, I.

AU - Cleator, J. H.

AU - Pulley, J. M.

AU - Mcpherson, J. A.

AU - Denny, J. C.

AU - Laposata, Michael

AU - Roden, D. M.

AU - Johnson, K. B.

PY - 2016

Y1 - 2016

N2 - Physician responses to genomic information are vital to the success of precision medicine initiatives. We prospectively studied a pharmacogenomics implementation program for the propensity of clinicians to select antiplatelet therapy based on CYP2C19 loss-of-function variants in stented patients. Among 2,676 patients, 514 (19.2%) were found to have a CYP2C19 variant affecting clopidogrel metabolism. For the majority (93.6%) of the cohort, cardiologists received active and direct notification of CYP2C19 status. Over 12 months, 57.6% of poor metabolizers and 33.2% of intermediate metabolizers received alternatives to clopidogrel. CYP2C19 variant status was the most influential factor impacting the prescribing decision (hazard ratio [HR] in poor metabolizers 8.1, 95% confidence interval [CI] [5.4, 12.2] and HR 5.0, 95% CI [4.0, 6.3] in intermediate metabolizers), followed by patient age and type of stent implanted. We conclude that cardiologists tailored antiplatelet therapy for a minority of patients with a CYP2C19 variant and considered both genomic and nongenomic risks in their clinical decision-making.

AB - Physician responses to genomic information are vital to the success of precision medicine initiatives. We prospectively studied a pharmacogenomics implementation program for the propensity of clinicians to select antiplatelet therapy based on CYP2C19 loss-of-function variants in stented patients. Among 2,676 patients, 514 (19.2%) were found to have a CYP2C19 variant affecting clopidogrel metabolism. For the majority (93.6%) of the cohort, cardiologists received active and direct notification of CYP2C19 status. Over 12 months, 57.6% of poor metabolizers and 33.2% of intermediate metabolizers received alternatives to clopidogrel. CYP2C19 variant status was the most influential factor impacting the prescribing decision (hazard ratio [HR] in poor metabolizers 8.1, 95% confidence interval [CI] [5.4, 12.2] and HR 5.0, 95% CI [4.0, 6.3] in intermediate metabolizers), followed by patient age and type of stent implanted. We conclude that cardiologists tailored antiplatelet therapy for a minority of patients with a CYP2C19 variant and considered both genomic and nongenomic risks in their clinical decision-making.

UR - http://www.scopus.com/inward/record.url?scp=84975780844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975780844&partnerID=8YFLogxK

U2 - 10.1002/cpt.331

DO - 10.1002/cpt.331

M3 - Article

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -